logo
BWX Technologies Reports Second Quarter 2025 Results

BWX Technologies Reports Second Quarter 2025 Results

Yahoo2 days ago
2Q25 revenues of $764.0 million
2Q25 net income of $78.5 million, adjusted EBITDA(1) of $145.9 million
2Q25 diluted GAAP EPS of $0.85, non-GAAP(1) EPS of $1.02
Closed acquisition of Kinectrics, Inc. on May 20, 2025
Signed pricing agreement for naval reactors and components; booked over $1.0 billion of $2.6 billion total contract value
Record backlog of $6.0 billion, up 70.2% year-over-year
Raising 2025 adjusted EBITDA(1) guidance to $565 million-$575 million and non-GAAP EPS(1) guidance to $3.65-$3.75; free cash flow guidance increased to $275 million-$285 million
LYNCHBURG, Va., August 04, 2025--(BUSINESS WIRE)--BWX Technologies, Inc. (NYSE: BWXT) ("BWXT", "we", "us" or the "Company") reported second quarter 2025 results. A reconciliation of non-GAAP results is detailed in Exhibit 1.
"We had exceptionally strong second quarter 2025 financial results driven by solid operational performance and pacing of work, particularly in Government Operations, which was complemented by robust bookings in both segments, leading to record backlog," said Rex D. Geveden, president and chief executive officer.
"The demand for nuclear solutions in the global security, clean energy, and medical markets continues to accelerate," continued Geveden. "In our ten years as a standalone public company, BWXT has built significant industrial scale, leading to one of the broadest and highest quality portfolios in the nuclear market. Our robust manufacturing, processing, and servicing capabilities stem from decades of real nuclear experience and our strategic investments in innovation and efficiency; these are underpinned by our technical depth and long history of successfully delivering nuclear solutions to our customers. We remain focused on growth, operational excellence, and strategic investments to create value for our customers, and ultimately our shareholders."
"Based on our strong year-to-date results, robust bookings, and favorable market outlook, we are increasing our 2025 financial guidance metrics," said Geveden. "We now expect adjusted EBITDA of $565 million to $575 million, adjusted EPS of $3.65 to $3.75, and free cash flow of $275 million to $285 million."
Financial Results Summary
Three Months Ended June 30,
2025
2024
$ Change
% Change
(Unaudited)
(In millions, except per share amounts)
Revenues
Government Operations
$
589.0
$
540.8
$
48.1
9%
Commercial Operations
$
176.1
$
141.5
$
34.6
24%
Consolidated
$
764.0
$
681.5
$
82.6
12%
Operating Income
Government Operations
$
109.4
$
92.5
$
16.9
18%
Commercial Operations
$
6.9
$
16.6
$
(9.8
)
(59)%
Unallocated Corporate (Expense)
$
(13.9
)
$
(10.3
)
$
(3.5
)
NM
Consolidated
$
102.4
$
98.8
$
3.6
4%
Consolidated non-GAAP(1)
$
118.6
$
104.6
$
14.0
13%
EPS (Diluted)
GAAP
$
0.85
$
0.79
$
0.06
8%
Non-GAAP(1)
$
1.02
$
0.82
$
0.20
24%
Net Income
GAAP
$
78.5
$
73.0
$
5.4
7%
Non-GAAP(1)
$
93.2
$
75.4
$
17.8
24%
Adjusted EBITDA(1)
Government Operations
$
133.0
$
108.2
$
24.8
23%
Commercial Operations
$
16.2
$
22.5
$
(6.3
)
(28)%
Unallocated Corporate
$
(3.3
)
$
(4.5
)
$
1.2
NM
Consolidated
$
145.9
$
126.2
$
19.7
16%
Cash Flows
Operating Cash Flow(2)
$
159.0
$
65.9
$
93.1
141%
Capital Expenditures(2)
$
32.7
$
30.4
$
2.3
8%
Free Cash Flow(1)
$
126.3
$
35.5
$
90.8
256%
Dividends Paid(2)
$
23.1
$
22.0
$
1.2
5%
NM = Not Meaningful
(1) A reconciliation of non-GAAP results are detailed in Exhibit 1. Additional information can be found in the materials on the BWXT investor relations website at www.bwxt.com/investors.
(2) Items named in the Financial Results Summary differ from names in BWXT Financial Statement. Operating Cash Flow = Net Cash Provided by Operating Activities; Capital Expenditures = Purchases of Property, Plant and Equipment; Dividends Paid = Dividends Paid to Common Shareholders
Revenues
Second quarter revenue increased in both operating segments. The Government Operations increase was driven by higher naval nuclear component production, special materials processing, and contribution from the acquisition of A.O.T., partially offset by lower microreactor volumes. The Commercial Operations increase was driven by higher revenue associated with commercial nuclear components, higher medical sales, and contribution from the acquisition of Kinectrics, partially offset by lower field services activity due to the timing of life-extension and outage projects, as well as lower fuel handling revenue.
Operating Income and Adjusted EBITDA(1)
Second quarter GAAP operating income increased as an increase in Government Operations was partially offset by lower Commercial Operations and higher corporate expense, as well as restructuring and transformation, and acquisition related costs.
Second quarter non-GAAP(1) operating income increased as an increase in Government Operations and lower corporate expense was partially offset by lower Commercial Operations. The Government Operations increase was driven by higher revenue and solid operational performance. The decrease in Commercial Operations was mainly due to revenue mix, related to the timing of life-extension and outage projects mentioned above, and growth investments.
Second quarter adjusted EBITDA(1) increased for the reasons noted above.
EPS
Second quarter GAAP EPS increased as higher operating income, higher other income and a lower tax rate, were partially offset by higher interest expense. Non-GAAP EPS(1) increased as higher operating income, higher other income and a lower tax rate were partially offset by higher interest expense.
Cash Flows
Second quarter operating cash flow increased driven by higher net income, working capital management, and timing of awards. Capital expenditures increased slightly due to timing of select growth investments, including the previously announced expansion of the Cambridge manufacturing plant that supports the commercial nuclear market.
Dividend
BWXT paid $23.1 million, or $0.25 per common share, to shareholders in the second quarter of 2025. On July 30, 2025, the BWXT Board of Directors declared a quarterly cash dividend of $0.25 per common share payable on September 5, 2025, to shareholders of record on August 18, 2025.
2025 Guidance
BWXT raised its 2025 guidance for revenue, adjusted EBITDA(1) and non-GAAP EPS(1), and increased the low-end its free cash flow guidance.
(In millions, except per share amounts)
Year Ended
Year Ending
Year Ending
December 31, 2024
December 31, 2025
December 31, 2025
Results
Current Guidance
Prior Guidance
Revenue
$2,704
~$3,100
~$3,000
Adjusted EBITDA(1)
$499
~$565 - $575
~$550 - $570
Non-GAAP(1) Earnings Per Share
$3.33
~$3.65 - $3.75
~$3.40 - $3.55
Free Cash Flow(1)
$255
$275 - $285
$265 - $285
Additional information can be found in the second quarter 2025 earnings call presentation on the BWXT investor relations website at www.bwxt.com/investors. The Company does not provide GAAP guidance because it is unable to reliably forecast most of the items that are excluded from GAAP to calculate non-GAAP results. These items could cause GAAP results to differ materially from non-GAAP results.
Conference Call to Discuss Second Quarter 2025 Results
Date:
Monday, August 4, 2025, at 5:00 p.m. EDT
Live Webcast:
Investor Relations section of website at www.bwxt.com
Full Earnings Release Available on BWXT Website
A full version of this earnings release is available on our Investor Relations website at http://investors.bwxt.com/2Q2025-release.
BWXT may use its website (www.bwxt.com) as a channel of distribution of material Company information. Financial and other important information regarding BWXT is routinely accessible through and posted on our website. In addition, you may elect to automatically receive e-mail alerts and other information about BWXT by enrolling through the "Email Alerts" section of our website at http://investors.bwxt.com.
Non-GAAP Measures
BWXT uses and makes reference to adjusted EBITDA, non-GAAP EPS, free cash flow and free cash flow conversion, which are not recognized measures under GAAP. BWXT is providing these non-GAAP measures to supplement the results provided in accordance with GAAP and it should not be considered superior to, or as a substitute for, the comparable GAAP measures. BWXT believes the non-GAAP measures provide meaningful insight and transparency into the Company's operational performance and provides these measures to investors to help facilitate comparisons of operating results with prior periods and to assist them in understanding BWXT's ongoing operations. Definitions for the non-GAAP measures are provided below and reconciliations are detailed in Exhibit 1, except that reconciliations of forward-looking GAAP measures are not provided because the company is unable to reliably forecast most of the items that are excluded from GAAP to calculate non-GAAP results. Other companies may define these measures differently or may utilize different non-GAAP measures, thus impacting comparability.
Non-GAAP Earnings Per Share (EPS) is calculated using GAAP EPS less the non-operational tax effected per share impact of pension & OPEB mark-to-market gains or losses and other one-time items, such as restructuring, transformation, acquisition-related costs, and acquisition-related amortization.
Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (EBITDA) is calculated using non-GAAP net income, plus provision for income taxes, less other – net, less interest income, plus interest expense, plus depreciation and amortization.
Adjusted pre-tax income is non-GAAP income before provision for income taxes.
Free Cash Flow (FCF) is calculated using net income to derive net cash provided by (used in) operating activities less purchases of property, plant and equipment.
Free Cash Flow conversion is free cash flow divided by net income.
Non-GAAP Adjustments
Our GAAP financial results detailed in Exhibit 1 have been adjusted for the following items:
Restructuring and Transformation Costs: Restructuring and transformation costs include restructuring charges as well as costs associated with our efforts to optimize underlying business processes through investments in information technology, process improvements and the implementation of strategic actions and initiatives which we deem to be incremental and non-recurring in nature.
Acquisition-related Costs: Acquisition-related costs relate to third-party professional service costs and one-time incremental costs associated with due diligence activities and efforts to integrate the acquired business with our legacy operations.
Forward-Looking Statements
BWXT cautions that this release contains forward-looking statements, including, without limitation, statements relating to backlog, to the extent they may be viewed as an indicator of future revenues; our plans and expectations for each of our reportable segments, including growth opportunities and the expectations, timing and revenue of our strategic initiatives, such as medical radioisotopes, SMR components and recent acquisitions; disruptions to our supply chain and/or operations, changes in government regulations and other factors; and our expectations and guidance for 2025 and beyond. These forward-looking statements are based on management's current expectations and involve a number of risks and uncertainties, including, among other things, our ability to execute contracts in backlog; federal budget uncertainty, the risk of future budget cuts, the impact of continuing resolution funding mechanisms and the debt ceiling, the potential for government shutdowns and changing funding and acquisition priorities; the demand for and competitiveness of nuclear products and services; capital priorities of power generating utilities and other customers; the timing of technology development, regulatory approvals and automation of production; the receipt and/or timing of government approvals; the potential recurrence of subsequent waves or strains of COVID-19 or similar diseases; labor market challenges, including employee retention and recruitment; adverse changes in the industries in which we operate; and delays, changes or termination of contracts in backlog. If one or more of these risks or other risks materialize, actual results may vary materially from those expressed. For a more complete discussion of these and other risk factors, see BWXT's filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended December 31, 2024 and subsequent Form 10-Q filings. BWXT cautions not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and undertakes no obligation to update or revise any forward-looking statement, except to the extent required by applicable law.
About BWXT
At BWX Technologies, Inc. (NYSE: BWXT), we are People Strong, Innovation Driven. A U.S.-based company, BWXT is a Fortune 1000 and Defense News Top 100 manufacturing and engineering innovator that provides safe and effective nuclear solutions for global security, clean energy, environmental restoration, nuclear medicine and space exploration. With nearly 10,000 employees, BWXT and its affiliated companies have 20 major operating sites in the U.S., Canada and the U.K. BWXT and its industry partners support the U.S. Department of Energy and National Nuclear Security Administration across more than a dozen major contracts in North America. For more information, visit www.bwxt.com. Follow us on LinkedIn, X, Facebook and Instagram.
(1) A reconciliation of non-GAAP results are detailed in Exhibit 1. Additional information can be found in the materials on the BWXT investor relations website at www.bwxt.com/investors.
EXHIBIT 1
BWX TECHNOLOGIES, INC.
RECONCILIATION OF NON-GAAP OPERATING INCOME AND EARNINGS PER SHARE(1)(2)(3)
(In millions, except per share amounts)
Three Months Ended June 30, 2025
GAAP
Restructuring
&
Transformation
Costs
Acquisition-
Related Costs
Acquisition-
Related
Amortization
Non-GAAP
Government Operations Operating Income
$
109.4
$
0.9
$
3.5
$
1.8
$
115.6
Commercial Operations Operating Income
$
6.9
$
1.0
$
2.1
$
0.7
$
10.7
Unallocated Corporate Operating Income
$
(13.9
)
$
7.1
$
1.7
$

$
(5.1
)
Operating Income
$
102.4
$
9.0
$
7.2
$
2.5
$
121.1
Other Income (Expense)
(4.7
)



(4.7
)
Income Before Provision for Income Taxes
97.8
9.0
7.2
2.5
116.5
Provision for Income Taxes
(19.3
)
(1.4
)
(2.0
)
(0.6
)
(23.3
)
Net Income
78.5
7.6
5.3
1.9
93.2
Net Income Attributable to Noncontrolling Interest
(0.1
)



(0.1
)
Net Income Attributable to BWXT
$
78.4
$
7.6
$
5.3
$
1.9
$
93.1
Diluted Shares Outstanding
91.7
91.7
Diluted Earnings per Common Share
$
0.85
$
0.08
$
0.06
$
0.02
$
1.02
Effective Tax Rate
19.7
%
20.0
%
Three Months Ended June 30, 2024
GAAP
Restructuring
Costs
Acquisition-
Related Costs
One-Time
Tax Benefit
Non-GAAP
Government Operations Operating Income
$
92.5
$
0.3
$

$

$
92.8
Commercial Operations Operating Income
$
16.6
$
1.5
$

$

$
18.1
Unallocated Corporate Operating Income
$
(10.3
)
$
4.0
$
0.1
$

$
(6.3
)
Operating Income
$
98.8
$
5.8
$
0.1
$

$
104.6
Other Income (Expense)
(7.2
)



(7.2
)
Income Before Provision for Income Taxes
91.6
5.8
0.1

97.4
Provision for Income Taxes
(18.6
)
(1.3
)
(0.0
)
(2.2
)
(22.1
)
Net Income
73.0
4.4

(2.2
)
75.4
Net Income Attributable to Noncontrolling Interest
(0.1
)



(0.1
)
Net Income Attributable to BWXT
$
73.0
$
4.4
$

$
(2.2
)
$
75.3
Diluted Shares Outstanding
91.8
91.8
Diluted Earnings per Common Share
$
0.79
$
0.05
$
0.00
$
(0.02
)
$
0.82
Effective Tax Rate
20.3
%
22.7
%
EXHIBIT 1 (continued)
RECONCILIATION OF CONSOLIDATED ADJUSTED EBITDA(1)(2)(3)
(In millions)
Three Months Ended June 30, 2025
GAAP
Restructuring
&
Transformation
Costs
Acquisition-
related Costs
Acquisition-
related
Amortization
Non-GAAP
Net Income
$
78.5
$
7.6
$
5.3
$
1.9
$
93.2
Provision for Income Taxes
19.3
1.4
2.0
0.6
23.3
Other – net
(6.5
)



(6.5
)
Interest Expense
11.7



11.7
Interest Income
(0.6
)



(0.6
)
Depreciation & Amortization
27.3


(2.5
)
24.8
Adjusted EBITDA
$
129.7
$
9.0
$
7.2
$

$
145.9
Three Months Ended June 30, 2024
GAAP
Restructuring
Costs
Acquisition-
related Costs
One-Time
Tax Benefit
Non-GAAP
Net Income
$
73.0
$
4.4
$
0.0
$
(2.2
)
$
75.4
Provision for Income Taxes
18.6
1.3
0.0
2.2
22.1
Other – net
(3.0
)



(3.0
)
Interest Expense
10.7



10.7
Interest Income
(0.5
)



(0.5
)
Depreciation & Amortization
21.6



21.6
Adjusted EBITDA
$
120.4
$
5.8
$
0.1
$

$
126.2
RECONCILIATION OF REPORTING SEGMENT ADJUSTED EBITDA(1)(2)(3)(4)
(In millions)
Three Months Ended June 30, 2025
Operating
Income
(GAAP)
Non-GAAP
Adjustments(3,4)
Acquisition-
related
Amortization
Depreciation &
Amortization
Adjusted
EBITDA
Government Operations
$
109.4
$
4.4
$
1.8
$
17.4
$
133.0
Commercial Operations
$
6.9
$
3.1
$
0.7
$
5.6
$
16.2
Unallocated Corporate
$
(13.9
)
$
8.8
$

$
1.8
$
(3.3
)
Three Months Ended June 30, 2024
Operating
Income
(GAAP)
Non-GAAP
Adjustments(3)
Depreciation &
Amortization
Adjusted
EBITDA
Government Operations
$
92.5
$
0.3
$
15.4
$
108.2
Commercial Operations
$
16.6
$
1.5
$
4.4
$
22.5
Unallocated Corporate
$
(13.9
)
$
4.0
$
1.8
$
(4.5
)
EXHIBIT 1 (continued)
RECONCILIATION OF CONSOLIDATED FREE CASH FLOW(1)(2)(3)
(In millions)
Three Months Ended June 30, 2025
Net Cash Provided By Operating Activities
$
159.0
Purchases of Property, Plant and Equipment
(32.7
)
Free Cash Flow
$
126.3
Three Months Ended June 30, 2024
Net Cash Provided By Operating Activities
$
65.9
Purchases of Property, Plant and Equipment
(30.4
)
Free Cash Flow
$
35.5
(1)
Tables may not foot due to rounding.
(2)
BWXT is providing non-GAAP information regarding certain of its historical results and guidance on future earnings per share to supplement the results provided in accordance with GAAP and it should not be considered superior to, or as a substitute for, the comparable GAAP measures. BWXT believes the non-GAAP measures provide meaningful insight and transparency into the Company's operational performance and provides these measures to investors to help facilitate comparisons of operating results with prior periods and to assist them in understanding BWXT's ongoing operations.
(3)
For Non-GAAP adjustment details, see reconciliation of non-GAAP operating income and earnings per share.
(4)
Excludes acquisition-related amortization
BWX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
(Unaudited)
(In thousands, except share and per share amounts)
Revenues
$
764,039
$
681,465
$
1,446,297
$
1,285,431
Costs and Expenses:
Cost of operations
572,642
513,196
1,089,707
968,553
Research and development costs
4,565
1,271
6,578
2,761
(Gains) Losses on asset disposals and impairments, net
13
(4
)
(4,418
)
(4
)
Selling, general and administrative expenses
102,940
79,780
190,509
147,141
Total Costs and Expenses
680,160
594,243
1,282,376
1,118,451
Equity in Income of Investees
18,545
11,584
35,133
24,787
Operating Income
102,424
98,806
199,054
191,767
Other Income (Expense):
Interest income
551
540
1,273
1,386
Interest expense
(11,741
)
(10,688
)
(19,735
)
(20,283
)
Other – net
6,525
2,971
8,984
7,136
Total Other Income (Expense)
(4,665
)
(7,177
)
(9,478
)
(11,761
)
Income before Provision for Income Taxes
97,759
91,629
189,576
180,006
Provision for Income Taxes
19,297
18,584
35,588
38,427
Net Income
$
78,462
$
73,045
$
153,988
$
141,579
Net Income Attributable to Noncontrolling Interest
(74
)
(73
)
(138
)
(139
)
Net Income Attributable to BWX Technologies, Inc.
$
78,388
$
72,972
$
153,850
$
141,440
Earnings per Common Share:
Basic:
Net Income Attributable to BWX Technologies, Inc.
$
0.86
$
0.80
$
1.68
$
1.54
Diluted:
Net Income Attributable to BWX Technologies, Inc.
$
0.85
$
0.79
$
1.68
$
1.54
Shares used in the computation of earnings per share:
Basic
91,542,967
91,564,263
91,568,526
91,559,824
Diluted
91,702,703
91,801,539
91,788,204
91,831,232
BWX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
Six Months Ended June 30,
2025
2024
(Unaudited) (In thousands)
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income
$
153,988
$
141,579
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization
51,171
42,160
Income of investees, net of dividends
(2,700
)
(3,301
)
(Gains) Losses on asset disposals and impairments - net
(4,418
)
(4
)
Recognition of losses for pension and postretirement plans
1,627
1,663
Stock-based compensation expense
13,735
10,279
Other, net
(9,366
)
(28
)
Changes in assets and liabilities, net of effects from acquisitions:
Accounts receivable
(465
)
(20,319
)
Accounts payable
6,875
47,018
Retainages
(7,045
)
587
Contracts in progress and advance billings on contracts
7,754
(78,722
)
Income taxes
22,558
(6,741
)
Accrued and other current liabilities
19,382
(328
)
Pension liabilities, accrued postretirement benefit obligations and employee benefits
(33,656
)
(23,625
)
Other, net
(9,747
)
(11,298
)
NET CASH PROVIDED BY OPERATING ACTIVITIES
209,693
98,920
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment
(66,098
)
(60,827
)
Acquisition of businesses, net of cash acquired
(538,184
)

Sales and maturities of securities
3,397

Investments, net of return of capital, in equity method investees
(33,000
)

Other, net
4,405
203
NET CASH USED IN INVESTING ACTIVITIES
(629,480
)
(60,624
)
CASH FLOWS FROM FINANCING ACTIVITIES:
Borrowings of long-term debt
758,400
241,400
Repayments of long-term debt
(284,650
)
(239,525
)
Repurchases of common stock
(30,000
)
(20,000
)
Dividends paid to common shareholders
(46,798
)
(44,373
)
Cash paid for shares withheld to satisfy employee taxes
(12,883
)
(6,941
)
Settlements of forward contracts, net
1,657
4,543
Other, net
100
(108
)
NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES
385,826
(65,004
)
EFFECTS OF EXCHANGE RATE CHANGES ON CASH
(2,475
)
(308
)
TOTAL DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS
(36,436
)
(27,016
)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD
80,571
81,615
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH AND CASH EQUIVALENTS AT END OF PERIOD
$
44,135
$
54,599
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid during the period for:
Interest
$
30,036
$
32,181
Income taxes (net of refunds)
$
11,890
$
45,382
SCHEDULE OF NON-CASH INVESTING ACTIVITY:
Accrued capital expenditures included in accounts payable
$
15,575
$
9,273
BWX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
ASSETS
June 30, 2025
December 31, 2024
(Unaudited)
(In thousands)
Current Assets:
Cash and cash equivalents
$
36,984
$
74,109
Restricted cash and cash equivalents
3,049
2,785
Accounts receivable – trade, net
148,756
99,112
Accounts receivable – other
24,508
53,199
Retainages
40,712
33,667
Contracts in progress
639,601
577,745
Inventories
51,560
40,288
Other current assets
51,715
49,092
Total Current Assets
996,885
929,997
Property, Plant and Equipment, Net
1,537,771
1,278,161
Investments
7,572
10,609
Goodwill
512,602
287,362
Deferred Income Taxes
4,727
6,569
Investments in Unconsolidated Affiliates
175,635
99,403
Intangible Assets
324,533
165,325
Other Assets
139,347
92,498
TOTAL ASSETS
$
3,699,072
$
2,869,924
BWX TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
LIABILITIES AND STOCKHOLDERS' EQUITY
June 30, 2025
December 31, 2024
(Unaudited)
(In thousands, except share
and per share amounts)
Current Liabilities:
Current portion of long-term debt
$
12,500
$
12,500
Accounts payable
191,500
158,077
Accrued employee benefits
83,274
77,234
Accrued liabilities – other
104,576
65,100
Advance billings on contracts
198,336
161,290
Total Current Liabilities
590,186
474,201
Long-Term Debt
1,519,728
1,042,970
Accumulated Postretirement Benefit Obligation
77,490
16,515
Environmental Liabilities
96,620
94,225
Pension Liability
108,215
82,602
Other Liabilities
122,927
79,007
Commitments and Contingencies
Stockholders' Equity:
Common stock, par value $0.01 per share, authorized 325,000,000 shares; issued 128,680,180 and 128,320,295 shares at June 30, 2025 and December 31, 2024, respectively
1,286
1,283
Preferred stock, par value $0.01 per share, authorized 75,000,000 shares; No shares issued


Capital in excess of par value
243,068
228,889
Retained earnings
2,394,737
2,287,151
Treasury stock at cost, 37,281,441 and 36,869,498 shares at June 30, 2025 and December 31, 2024, respectively
(1,431,542
)
(1,388,432
)
Accumulated other comprehensive income (loss)
(23,385
)
(48,211
)
Stockholders' Equity – BWX Technologies, Inc.
1,184,164
1,080,680
Noncontrolling interest
(258
)
(276
)
Total Stockholders' Equity
1,183,906
1,080,404
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY
$
3,699,072
$
2,869,924
BWX TECHNOLOGIES, INC.
BUSINESS SEGMENT INFORMATION
Three Months Ended June 30,
Six Months Ended June 30,
2025
2024
2025
2024
(Unaudited)
(In thousands)
REVENUES:
Government Operations
$
588,959
$
540,846
$
1,144,246
$
1,027,967
Commercial Operations
176,139
141,491
304,449
258,529
Eliminations
(1,059
)
(872
)
(2,398
)
(1,065
)
TOTAL
$
764,039
$
681,465
$
1,446,297
$
1,285,431
SEGMENT INCOME:
Government Operations
$
109,417
$
92,520
$
207,163
$
178,206
Commercial Operations
6,877
16,628
13,342
25,219
SUBTOTAL
$
116,294
$
109,148
$
220,505
$
203,425
Unallocated Corporate
(13,870
)
(10,342
)
(21,451
)
(11,658
)
TOTAL
$
102,424
$
98,806
$
199,054
$
191,767
DEPRECIATION AND AMORTIZATION:
Government Operations
$
19,222
$
15,431
$
37,318
$
29,664
Commercial Operations
6,243
4,397
10,262
8,841
Corporate
1,794
1,781
3,591
3,655
TOTAL
$
27,259
$
21,609
$
51,171
$
42,160
CAPITAL EXPENDITURES:
Government Operations
$
15,770
$
14,201
$
34,270
$
30,584
Commercial Operations
16,701
15,736
29,910
29,080
Corporate
258
468
1,918
1,163
TOTAL
$
32,729
$
30,405
$
66,098
$
60,827
BACKLOG:
Government Operations
$
4,435,593
$
2,865,193
$
4,435,593
$
2,865,193
Commercial Operations
1,579,598
669,054
1,579,598
669,054
TOTAL
$
6,015,191
$
3,534,247
$
6,015,191
$
3,534,247
BOOKINGS:
Government Operations
$
1,412,286
$
497,021
$
1,638,683
$
676,434
Commercial Operations
228,195
83,183
721,615
145,597
TOTAL
$
1,640,481
$
580,204
$
2,360,298
$
822,031
View source version on businesswire.com: https://www.businesswire.com/news/home/20250804605853/en/
Contacts
Investor Contact: Chase JacobsonVice President, Investor Relations980-365-4300Investors@bwxt.com
Media Contact: John DobkenSenior Manager, Media & Public Relations202-428-6913jcdobken@bwxt.com
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Yahoo

time18 minutes ago

  • Yahoo

Sana Biotechnology Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

SEATTLE, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA) ('Sana'), a company focused on changing the possible for patients through engineered cells, today announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, Sana intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares of common stock and pre-funded warrants to be sold in the proposed offering will be sold by Sana. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering. Morgan Stanley, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the proposed offering. The proposed offering is being made pursuant to a Registration Statement on Form S-3, including a base prospectus, previously filed with and declared effective by the SEC, and Sana will file a preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the proposed offering, copies of which can be accessed for free through the SEC's website at When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the proposed offering may also be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014 or by email at prospectus@ Goldman Sachs & Co. LLC, Attn: Prospectus Department, at 200 West Street, New York, NY 10282, by telephone at (866) 471-2526 or by email at prospectus-ny@ BofA Securities, Attn: Prospectus Department, NC1-022-02-25, 201 North Tryon Street, Charlotte, NC 28255-0001 or by email at or TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, New York 10017, by telephone at (855) 495-9846 or by email at This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction. About Sana Biotechnology Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements about Sana Biotechnology, Inc. (the 'Company,' 'we,' 'us,' or 'our') within the meaning of the federal securities laws, including those related to the completion, timing, and size of the proposed offering and our intent to grant the underwriters a 30-day option to purchase additional shares. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: whether or not we will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled 'Risk Factors' in documents that we file from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the proposed public offering. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Investor Relations & Media: Nicole in to access your portfolio

Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025
Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025

Yahoo

time18 minutes ago

  • Yahoo

Informa TechTarget to Announce Q2 2025 Financial Results on August 12, 2025

Live Conference Call and Webcast Scheduled to Begin at 8:30 a.m. ET on August 12, 2025 NEWTON, Mass., August 06, 2025--(BUSINESS WIRE)--TechTarget, Inc. (Nasdaq: TTGT) ("Informa TechTarget" or the "Company"), a leading growth accelerator for the B2B Technology sector, today announced that it will release its Q2 2025 financial results for the three months ended June 30, 2025 before the market opens on Tuesday, August 12, 2025. The Company's Chief Executive Officer, Gary Nugent, and Chief Financial Officer, Dan Noreck, will host a live conference call and webcast at 8:30 a.m. Eastern Time on that day to discuss the Company's financial results and outlook. The Q2 2025 financial results will be available prior to the conference call and webcast on the investor relations section of the Company's website at Conference Call Dial-In Information: United States (Toll Free): 1-833-470-1428 United States: 1-404-975-4839 United Kingdom (Toll Free): +44 808 189 6484 United Kingdom: +44 20 8068 2558 Global Dial-in Numbers Access code: 967110 Please access the call at least 10 minutes prior to the time the conference is set to begin. Please ask to be joined into the Informa TechTarget call. Conference Call Webcast Information: This webcast can be accessed via Informa TechTarget's website at Conference Call Replay Information: A replay of the conference call will be available via telephone beginning one (1) hour after the conference call through September 11, 2025 at 11:59 p.m. ET. To hear the replay: United States (Toll Free): 1-866-813-9403 United States: 1-929-458-6194 Access Code: 703085 A web version will also be available for replay during the same period on Informa TechTarget's website at About Informa TechTarget TechTarget, Inc. (Nasdaq: TTGT), which also refers to itself as Informa TechTarget, informs, influences and connects the world's technology buyers and sellers, helping accelerate growth from R&D to ROI. With a vast reach of over 220 highly targeted technology-specific websites and over 50 million permissioned first-party audience members, Informa TechTarget has a unique understanding of and insight into the technology market. Underpinned by those audiences and their data, we offer expert-led, data-driven, and digitally enabled services that have the potential to deliver significant impact and measurable outcomes to our clients: Trusted information that shapes the industry and informs investment Intelligence and advice that guides and influences strategy Advertising that grows reputation and establishes thought leadership Custom content that engages and prompts action Intent and demand generation that more precisely targets and converts Informa TechTarget is headquartered in Boston, MA and has offices in 19 global locations. For more information, visit and follow us on LinkedIn. © 2025 TechTarget, Inc. All rights reserved. All trademarks are the property of their respective owners. View source version on Contacts Investor Inquiries Daniel NoreckMitesh KotechaInforma TechTarget617-431-9200investor@ Media Inquiries Garrett MannCorporate CommunicationsInforma

Corteva Delivers Strong 1H 2025, Raises Full-Year Guidance
Corteva Delivers Strong 1H 2025, Raises Full-Year Guidance

Yahoo

time18 minutes ago

  • Yahoo

Corteva Delivers Strong 1H 2025, Raises Full-Year Guidance

Seed 1H results reflect leading North America corn and soybean portfolio market position and operational execution Crop Protection 1H results driven by broad-based volume growth and ongoing cost improvement Full-year 2025 guidance3 increased to reflect strong first half performance, incremental benefits on controllable levers, and growth platforms Share buyback program and dividend increase demonstrate strong balance sheet and cash flow INDIANAPOLIS, Aug. 6, 2025 /PRNewswire/ -- Corteva, Inc. (NYSE: CTVA) ("Corteva" or the "Company") today reported financial results for the second quarter and six months ended June 30, 2025. 2Q 2025 Results OverviewNet Sales Inc. from Cont. Ops (After Tax) EPS GAAP $6.46B $1.38B $2.02 vs. 2Q 2024 6 % 31 % 34 % Organic1 Sales Operating EBITDA1 Operating EPS1 NON-GAAP $6.54B $2.16B $2.20 vs. 2Q 2024 7 % 13 % 20 %1H 2025 Results OverviewNet Sales Inc. from Cont. Ops (After Tax) EPS GAAP $10.87B $2.05B $2.98 vs. 1H 2024 3 % 43 % 47 %Organic1 Sales Operating EBITDA1 Operating EPS1 NON-GAAP $11.15B $3.35B $3.33 vs. 1H 2024 5 % 14 % 22 % First Half 2025 Highlights Net sales increased 3% versus prior year. Organic1 sales increased 5% in the same period with gains in all regions. Seed net sales increased 2% and organic1 sales increased 5%. Price was up 3% led by North America2 and EMEA2 with continued execution on the Company's price for value strategy. Volume increased 2%, primarily reflecting increased corn area in North America2. Crop Protection net sales increased 3% and organic1 sales increased 6%. Volume increased 8%, driven by demand for new products and biologicals. Price declined 2% primarily due to the market dynamics in Latin America. GAAP income and earnings per share (EPS) from continuing operations were $2.05 billion and $2.98 per share, respectively. Operating EBITDA1 and Operating EPS1 were $3.35 billion, and $3.33 per share, respectively. The Company updated full-year 2025 guidance3 and expects net sales in the range of $17.6 billion to $17.8 billion. Operating EBITDA1 is expected to be in the range of $3.75 to $3.85 billion. Operating EPS1 is expected to be in the range of $3.00 to $3.20 per share. The Company expects to repurchase approximately $1 billion of shares during 2025. 1. Organic Sales, Operating EPS, and Operating EBITDA are non-GAAP measures. See page 6 for further discussion. 2. North America is defined as U.S. and Canada. EMEA is defined as Europe, Middle East and Africa. 3. The Company does not provide the most comparable GAAP measure on a forward-looking basis. See page 5 for further discussion. _________________________________________________________________________ "In the second quarter, farmers' drive to get the most out of every acre led to higher demand for our best-in-class seed and crop protection solutions. Coupled with our continued focus on cost discipline and operational excellence, this resulted in impressive margin expansion for the quarter. Turning to the first half of the year, growth platforms, cost discipline as well as our leadership of the North America corn and soybean market helped us deliver results that exceeded our expectations. While we continue to navigate a fluid macro environment, we are raising our full year guidance as a result of the strength of our global business and the setup for our Latin American business in the second half. This stronger view of 2025 also underscores our confidence in delivering our 2027 financial framework, and in the value our business offers, both in the short- and long-term." Chuck MagroChief Executive Officer _________________________________________________________________________ Summary of Second Quarter 2025For the second quarter ended June 30, 2025, net sales increased 6% versus the same period last year. Organic1 sales increased 7%. Volume was up 6% versus prior year on growth in both Crop Protection and Seed. Crop Protection volume increased 11% over the prior year driven primarily by Latin America on demand for new products, fungicides, spinosyns, and biologicals. Seed volume increased 3% versus prior year due primarily to increased corn area and share gains in North America. Price was up 1% versus prior year, reflecting higher Seed pricing, partially offset by competitive price dynamics in Crop Protection, primarily in Latin America. GAAP income from continuing operations after income taxes was $1.38 billion in second quarter of 2025 compared to $1.06 billion in second quarter of 2024. Operating EBITDA1 for the second quarter of 2025 was $2.16 billion, up 13% compared to prior year, translating into approximately 215 basis points of Operating EBITDA1 margin improvement.2Q 2Q % % ($ in millions, except where noted) 2025 2024 Change Organic1 Change Net Sales $6,456 $6,112 6 % 7 % North America $4,629 $4,400 5 % 6 % EMEA $747 $673 11 % 13 % Latin America $672 $650 3 % 11 % Asia Pacific $408 $389 5 % 6 % 1H 1H % % ($ in millions, except where noted) 2025 2024 Change Organic1 Change Net Sales $10,873 $10,604 3 % 5 % North America $6,839 $6,487 5 % 6 % EMEA $2,224 $2,261 (2) % 3 % Latin America $1,114 $1,165 (4) % 6 % Asia Pacific $696 $691 1 % 3 % Seed SummarySeed net sales were $4.54 billion in the second quarter of 2025, up from $4.33 billion in the second quarter of 2024. The sales increase reflects a 3% increase in volume, a 3% increase in price and a 1% unfavorable currency impact. Volume growth in the quarter reflects increased corn area and share gains in North America, partially offset by lower soybean area in North America and just-in-time seed purchases in Argentina, shifting sales to the second half. The increase in price is due primarily to demand for top technology and increased out-licensing income. Unfavorable currency impacts were led by the Canadian Dollar. Segment operating EBITDA was $1.86 billion in the second quarter of 2025, up 10% from the second quarter of 2024. Price execution and market share gains in North America, product mix, reduction of net royalty expense, and ongoing cost and productivity actions more than offset increased compensation and research expense, and the unfavorable impact of currency. Segment operating EBITDA margin improved by about 185 basis points versus the prior-year period. 2Q 2Q % % ($ in millions, except where noted) 2025 2024 Change Organic1 Change North America $3,954 3,753 5 % 6 % EMEA $282 $251 12 % 23 % Latin America $154 $207 (26) % (19) % Asia Pacific $147 $120 23 % 25 % Total 2Q Seed Net Sales $4,537 $4,331 5 % 6 % 2Q Seed Operating EBITDA $1,863 $1,698 10 % N/A Seed net sales were $7.24 billion in the first half of 2025, up 2% from the same period of 2024. The sales increase reflects a 3% increase in price and a 2% increase in volume, partially offset by a 3% unfavorable currency impact. Price gains in most regions, led by North America, demonstrate demand for top technology and the strength of the portfolio, coupled with increased out-licensing income. Volume growth was driven primarily by increased corn area and share gains in North America, partially offset by reduced 2024/2025 corn area and just-in-time seed purchases in Argentina, as well as lower soybean area in North America. Unfavorable currency impacts were led by the Brazilian Real and the Canadian dollar. Segment operating EBITDA was $2.71 billion for the first half of 2025, up 11% from the same period of 2024. Price execution and market share gains in North America, product mix, reduction of net royalty expense, and ongoing cost and productivity actions more than offset increased compensation and research expense and the unfavorable impact of currency. Segment operating EBITDA margin improved by 280 basis points versus the prior-year period.1H 1H % % ($ in millions, except where noted) 2025 2024 Change Organic1Change North America $5,551 $5,224 6 % 7 % EMEA $1,108 $1,169 (5) % 3 % Latin America $339 $478 (29) % (19) % Asia Pacific $246 $211 17 % 19 % Total 1H Seed Net Sales $7,244 $7,082 2 % 5 % 1H Seed Operating EBITDA $2,705 $2,446 11 % N/A Crop Protection SummaryCrop Protection net sales were approximately $1.92 billion in the second quarter of 2025 compared to approximately $1.78 billion in the second quarter of 2024. The sales increase over the prior period reflects an 11% increase in volume, partially offset by a 2% price decline and a 1% unfavorable impact from currency. The increase in volume was driven primarily by Latin America on demand for new products, fungicides, spinosyns, and biologicals. The price decline was primarily due to the competitive pricing environment in Latin America, partially offset by North America price increases. Unfavorable currency impacts were led by the Brazilian Real. Segment operating EBITDA was $334 million in the second quarter of 2025, up 31% from the second quarter of 2024. Raw material deflation, productivity savings, and volume growth more than offset the unfavorable impact of currency, price pressure, and higher compensation and bad debt expense in SG&A. Segment operating EBITDA margin improved by approximately 310 basis points versus the prior-year period. 2Q 2Q % % ($ in millions, except where noted) 2025 2024 Change Organic1 Change North America $675 $647 4 % 5 % EMEA $465 $422 10 % 7 % Latin America $518 $443 17 % 25 % Asia Pacific $261 $269 (3) % (2) % Total 2Q Crop Protection Net Sales $1,919 $1,781 8 % 9 % 2Q Crop Protection Operating EBITDA $334 $255 31 % N/A Crop Protection net sales were approximately $3.63 billion for the first half of 2025 compared to approximately $3.52 billion in the same period of 2024. The sales increase reflects an 8% increase in volume, partially offset by a 2% decline in price and a 3% unfavorable impact from currency. The price decline was primarily due to market dynamics in Latin America. The increase in volume was driven by demand for new products, fungicides and biologicals. Unfavorable currency impacts were led by the Brazilian Real and the Turkish Lira. Segment operating EBITDA was $711 million for the first half of 2025, up 26% from the same period last year. Raw material deflation, productivity savings, and volume growth more than offset the unfavorable impact of currency, price pressure, and higher compensation and bad debt expense in SG&A. Segment operating EBITDA margin improved by approximately 355 basis points versus the prior-year period.1H 1H % % ($ in millions, except where noted) 2025 2024 Change Organic1 Change North America $1,288 $1,263 2 % 3 % EMEA $1,116 $1,092 2 % 4 % Latin America $775 $687 13 % 23 % Asia Pacific $450 $480 (6) % (5) % Total 1H Crop Protection Net Sales $3,629 $3,522 3 % 6 % 1H Crop Protection Operating EBITDA $711 $565 26 % N/A 2025 Market Outlook & GuidanceFarmers continue to prioritize top-tier seed and crop protection technologies to maximize and protect their yields to keep pace with record global demand for grain and oilseeds. Global corn area is up in 2025, with a five percent increase in North America, driven by favorable corn economics relative to soybeans and other crops. Expectations for a large production year in 2025 and trade uncertainty have pressured grain prices in most major growing regions. However, the global corn stocks-to-use ratio for the 2025/2026 crop year is still expected to be at its lowest point in over a decade. In Crop Protection, our latest view of the market for the full year continues to be a "flattish" environment, with volume gains offset by pricing headwinds. For Corteva's Crop Protection business, we are expecting full-year double-digit volume gains in excess of low-single-digit pricing headwinds from broad-based portfolio gains, including new products and biologicals. As it pertains to ongoing tariff negotiations around the world, we are not expecting a material net impact on our full-year 2025 results given policies in place today. Global grain and oilseed demand is not expected to decline, regardless of any changes in trade flows. As a result of its strong first half performance and expectations for modest growth in the second half, the Company increased full-year 2025 guidance3 with net sales expected to be in the range of $17.6 billion to $17.8 billion, growth of ~5% at the mid-point. Operating EBITDA1 is expected to be $3.75 billion to $3.85 billion, growth of 13% at the mid-point. Operating EPS1 is expected to be $3.00 to $3.20 per share, growth of 21% at the mid-point. The Company expects to repurchase approximately $1.0 billion of shares in 2025. The Company is not able to reconcile its forward-looking non-GAAP financial measures, to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of its control, such as Significant Items, without unreasonable effort. Second Quarter Conference CallThe Company will host a live webcast of its second quarter 2025 earnings conference call with investors to discuss its results and outlook tomorrow, August 7, 2025, at 9:00 a.m. ET. The slide presentation that accompanies the conference call is posted on the Company's Investor Events and Presentations page. A replay of the webcast will also be available on the Investor Events and Presentations page. About CortevaCorteva, Inc. (NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world's most pressing agriculture challenges. Corteva generates advantaged market preference through its unique distribution strategy, together with its balanced and globally diverse mix of seed, crop protection, and digital products and services. With some of the most recognized brands in agriculture and a technology pipeline well positioned to drive growth, the company is committed to maximizing productivity for farmers, while working with stakeholders throughout the food system as it fulfills its promise to enrich the lives of those who produce and those who consume, ensuring progress for generations to come. More information can be found at Cautionary Statement About Forward-Looking StatementsThis press release contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like "plans," "expects," "will," "anticipates," "believes," "intends," "projects," "estimates," "outlook," or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva's financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements. Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the company's control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on the company's business, results of operations and financial condition. Some of the important factors that could cause the company's actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of the company's products; (ii) failure to successfully develop and commercialize the company's pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of the company's biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in the company's industry; (ix) competitor's establishment of an intermediary platform for distribution of the company's products; (x) risks related to recent funding and staff reductions at U.S. government agencies; (xi) risk related to geopolitical and military conflict; (xii) effect of volatility in the company's input costs; (xiii) risks related to the company's global operations; (xiv) effect of industrial espionage and other disruptions to the company's supply chain, information technology or network systems; (xv) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation of Corteva; (xvi) impact of the company's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xvii) failure of the company's customers to pay their debts to the company, including customer financing programs; (xviii) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xix) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to the company; (xx) increases in pension and other post-employment benefit plan funding obligations; (xxi) risks related to pandemics or epidemics; (xxii) capital markets sentiment towards sustainability matters; (xxiii) the company's intellectual property rights or defense against intellectual property claims asserted by others; (xxiv) effect of counterfeit products; (xxv) the company's dependence on intellectual property cross-license agreements; and (xxvi) other risks related to the Separation from DowDuPont. Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva's management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the "Risk Factors" section of Corteva's Annual Report on Form 10-K, as modified by subsequent Quarterly Reports on Forms 10-Q and Current Reports on Form 8-K. Regulation G (Non-GAAP Financial Measures)This earnings release includes information that does not conform to U.S. GAAP and are considered non-GAAP measures. These measures may include organic sales, organic growth (including by segment and region), operating EBITDA, operating earnings (loss) per share, and base income tax rate. Management uses these measures internally for planning and forecasting, including allocating resources and evaluating incentive compensation. Management believes that these non-GAAP measures best reflect the ongoing performance of the Company during the periods presented and provide more relevant and meaningful information to investors as they provide insight with respect to ongoing operating results of the Company and a more useful comparison of year over year results. These non-GAAP measures supplement the Company's U.S. GAAP disclosures and should not be viewed as an alternative to U.S. GAAP measures of performance. Furthermore, such non-GAAP measures may not be consistent with similar measures provided or used by other companies. Reconciliations for these non-GAAP measures to U.S. GAAP are provided in the Selected Financial Information and Non-GAAP Measures starting on page A-5 of the Financial Statement Schedules. Corteva is not able to reconcile its forward-looking non-GAAP financial measures to its most comparable U.S. GAAP financial measures, as it is unable to predict with reasonable certainty items outside of the Company's control, such as significant items, without unreasonable effort. For significant items reported in the periods presented, refer to page A-10 of the Financial Statement Schedules. Beginning January 1, 2020, the Company presents accelerated prepaid royalty amortization expense as a significant item. Accelerated prepaid royalty amortization represents the non-cash charge associated with the recognition of upfront payments made to Monsanto in connection with the Company's non-exclusive license in the United States and Canada for Monsanto's Genuity® Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits. Due to the ramp-up of Enlist E3TM, Corteva significantly reduced the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the trait platform thereafter. In 2023 and 2024, the company committed to restructuring activities to optimize the Crop Protection network of manufacturing and external partners, which are expected to be substantially complete in 2026. The company expects to record approximately $150 million to $165 million net pre-tax restructuring charges during 2025 for these activities. Organic sales is defined as price and volume and excludes currency and portfolio and other impacts, including significant items. Operating EBITDA is defined as earnings (loss) (i.e., income (loss) from continuing operations before income taxes) before interest, depreciation, amortization, non-operating benefits (costs), foreign exchange gains (losses), and net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting, excluding the impact of significant items. Non-operating benefits (costs) consists of non-operating pension and other post- employment benefit (OPEB) credits (costs), tax indemnification adjustments, and environmental remediation and legal costs associated with legacy businesses and sites. Tax indemnification adjustments relate to changes in indemnification balances, as a result of the application of the terms of the Tax Matters Agreement, between Corteva and Dow and/or DuPont that are recorded by the Company as pre-tax income or expense. Operating earnings (loss) per share is defined as "earnings (loss) per common share from continuing operations - diluted" excluding the after-tax impact of significant items, the after-tax impact of non-operating benefits (costs), the after-tax impact of amortization expense associated with intangible assets existing as of the Separation from DowDuPont, and the after-tax impact of net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting. Although amortization of the Company's intangible assets is excluded from these non-GAAP measures, management believes it is important for investors to understand that such intangible assets contribute to revenue generation. Amortization of intangible assets that relate to past acquisitions will recur in future periods until such intangible assets have been fully amortized. Any future acquisitions may result in amortization of additional intangible assets. Net unrealized gain or loss from mark-to-market activity for certain foreign currency derivative instruments that do not qualify for hedge accounting represents the non-cash net gain (loss) from changes in fair value of certain undesignated foreign currency derivative contracts. Upon settlement, which is within the same calendar year of execution of the contract, the realized gain (loss) from the changes in fair value of the non-qualified foreign currency derivative contracts will be reported in the relevant non-GAAP financial measures, allowing quarterly results to reflect the economic effects of the foreign currency derivative contracts without the resulting unrealized mark to fair value volatility. Base income tax rate is defined as the effective income tax rate less the effect of exchange gains (losses), significant items, amortization of intangibles (existing as of Separation), mark-to-market (gains) losses on certain foreign currency contracts not designated as hedges, and non-operating (benefits) costs. ® TM Corteva Agriscience and its affiliated companies. 8/6/2025 View original content to download multimedia: SOURCE Corteva Agriscience Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store